Effects of profit-reducing policies on firm survival, financial performance, and new drug introductions in the research-based pharmaceutical industry

Article Abstract:

The implications of a pharmaceutical company's financial policy and research and development (R&D) on R&D costs are computed using a new model. Results show that reducing profitability is significant in economic performance, survival and new product development of the firm, although it may remain unnoticed by consumers. Profit reduction in new and small pharmaceutical companies is examined.

Product development, Sales & consumption, Economic aspects, Pharmaceutical industry, Industry sales and revenue

---

Determinants of drug prices and expenditures

Article Abstract:

Analyzing the flow of money and products in the pharmaceutical industry is different in other industries owing to the presence of intermediaries and subscribers. Spending on drug research and development is related to increase in drug prices, that when spending increases, the prise also rises. The impacts of price controls in the pharmaceutical industry are also discussed.

General services, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Marketing procedures, Research Findings, Pharmaceutical Preparation Manufacturing, Commodity & service prices, Drugs, Pharmaceutical Preparations, Metabolic Agents NEC, Metabolic Agents, Purchasing, Prices and rates, Marketing research, Company pricing policy, Market research

---

Similar abstracts:

• Abstracts: The effect of Medicaid expansions on public insurance, private insurance, and redistribution. Generational aspects of Medicare
• Abstracts: A stochastic frontier approach to firm level efficiency, technological change, and productivity during the early transition in Hungary
• Abstracts: Does corporate performance improve after mergers? The challenges of investor communication: the case of CUC International, Inc
• Abstracts: Non-performance risk and transaction costs in laboratory forward and spot markets
• Abstracts: Earnings management and investor protection: an international comparison. Executive stock option repricing, internal governance mechanisms, and management turnover

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.